SUPPLEMENT

Q3 2020 — Sales of Key Products/Franchises

Q3 2020PDF · 4 pages214 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 	601	$ 	477 	26.0% 	26.0% 	- 	1,917	$ 	1,468 	30.6% 	30.6% 	-
Intl 	541 	621 	-12.9% 	-12.9% 	0.0% 	1,722 	1,781 	-3.3% 	-0.6% 	-2.7%
WW 	1,142 	1,098 	4.0% 	4.0% 	0.0% 	3,639 	3,249 	12.0% 	13.5% 	-1.5%
SKIN HEALTH / BEAUTY
(4)
US 	572 	559 	2.4% 	2.4% 	- 	1,767 	1,810 	-2.4% 	-2.4% 	-
Intl 	577 	592 	-2.7% 	-0.5% 	-2.2% 	1,506 	1,633 	-7.8% 	-4.9% 	-2.9%
WW 	1,149 	1,151 	-0.2% 	0.9% 	-1.1% 	3,273 	3,443 	-5.0% 	-3.6% 	-1.4%
ORAL CARE
US 	164 	156 	5.5% 	5.5% 	- 	510 	462 	10.4% 	10.4% 	-
Intl 	248 	223 	10.7% 	14.4% 	-3.7% 	694 	673 	3.0% 	7.9% 	-4.9%
WW 	412 	379 	8.5% 	10.8% 	-2.3% 	1,204 	1,135 	6.0% 	8.9% 	-2.9%
BABY CARE
US 	91 	91 	-1.0% 	-1.0% 	- 	279 	277 	0.5% 	0.5% 	-
Intl 	302 	326 	-7.2% 	-0.6% 	-6.6% 	831 	977 	-14.9% 	-8.6% 	-6.3%
WW 	393 	417 	-5.9% 	-0.7% 	-5.2% 	1,110 	1,254 	-11.5% 	-6.6% 	-4.9%
WOMEN'S HEALTH
US 	3 	3 	-6.9% 	-6.9% 	- 	10 	9 	7.3% 	7.3% 	-
Intl 	227 	252 	-9.6% 	-4.0% 	-5.6% 	654 	724 	-9.6% 	-2.8% 	-6.8%
WW 	230 	255 	-9.6% 	-4.1% 	-5.5% 	664 	733 	-9.4% 	-2.7% 	-6.7%
WOUND CARE / OTHER
US 	125 	109 	15.2% 	15.2% 	- 	370 	343 	8.0% 	8.0% 	-
Intl 	64 	59 	7.4% 	10.3% 	-2.9% 	175 	173 	1.3% 	5.4% 	-4.1%
WW 	189 	168 	12.5% 	13.5% 	-1.0% 	545 	516 	5.8% 	7.2% 	-1.4%
TOTAL CONSUMER HEALTH
US 	1,556 	1,394 	11.6% 	11.6% 	- 	4,853 	4,369 	11.1% 	11.1% 	-
Intl 	1,958 	2,075 	-5.6% 	-2.7% 	-2.9% 	5,582 	5,962 	-6.4% 	-2.2% 	-4.2%
WW 	3,514	$ 	3,469 	1.3% 	3.0% 	-1.7% 	10,435	$ 	10,331 	1.0% 	3.4% 	-2.4%
See footnotes at end of schedule
% Change 	% Change

-- 1 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,558	$ 	2,582 	-0.9% 	-0.9% 	- 	7,330	$ 	7,124 	2.9% 	2.9% 	-
Intl 	1,230 	1,129 	9.0% 	8.4% 	0.6% 	3,619 	3,304 	9.5% 	11.9% 	-2.4%
WW 	3,789 	3,711 	2.1% 	1.9% 	0.2% 	10,950 	10,428 	5.0% 	5.7% 	-0.7%
REMICADE
US 	634 	749 	-15.4% 	-15.4% 	- 	1,852 	2,324 	-20.3% 	-20.3% 	-
US Exports (6) 78 	88 	-11.3% 	-11.3% 	- 	321 	226 	42.1% 	42.1% 	-
Intl 	209 	299 	-30.1% 	-28.0% 	-2.1% 	673 	795 	-15.3% 	-11.6% 	-3.7%
WW 	921 	1,136 	-18.9% 	-18.4% 	-0.5% 	2,846 	3,345 	-14.9% 	-14.0% 	-0.9%
SIMPONI / SIMPONI ARIA
US 	312 	313 	-0.4% 	-0.4% 	- 	840 	857 	-2.0% 	-2.0% 	-
Intl 	280 	273 	2.4% 	2.2% 	0.2% 	827 	816 	1.3% 	3.9% 	-2.6%
WW 	592 	586 	0.9% 	0.8% 	0.1% 	1,667 	1,673 	-0.4% 	0.9% 	-1.3%
STELARA
US 	1,313 	1,212 	8.4% 	8.4% 	- 	3,668 	3,152 	16.4% 	16.4% 	-
Intl 	634 	487 	30.3% 	28.1% 	2.2% 	1,795 	1,509 	19.0% 	20.6% 	-1.6%
WW 	1,947 	1,698 	14.7% 	14.0% 	0.7% 	5,463 	4,661 	17.2% 	17.7% 	-0.5%
TREMFYA
US 	222 	221 	0.4% 	0.4% 	- 	650 	565 	15.0% 	15.0% 	-
Intl 	105 	69 	54.4% 	50.4% 	4.0% 	316 	177 	78.7% 	79.1% 	-0.4%
WW 	327 	290 	13.1% 	12.2% 	0.9% 	965 	742 	30.2% 	30.3% 	-0.1%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	3 	2 	35.6% 	44.6% 	-9.0% 	9 	8 	12.4% 	19.1% 	-6.7%
WW 	3 	2 	35.6% 	44.6% 	-9.0% 	9 	8 	12.4% 	19.1% 	-6.7%
INFECTIOUS DISEASES
US 	413 	418 	-1.1% 	-1.1% 	- 	1,265 	1,162 	8.9% 	8.9% 	-
Intl 	451 	421 	7.0% 	6.3% 	0.7% 	1,397 	1,385 	0.9% 	3.8% 	-2.9%
WW 	864 	839 	3.0% 	2.6% 	0.4% 	2,662 	2,547 	4.5% 	6.1% 	-1.6%
EDURANT / rilpivirine
US 	11 	12 	-12.0% 	-12.0% 	- 	33 	36 	-8.6% 	-8.6% 	-
Intl 	226 	206 	9.3% 	5.0% 	4.3% 	684 	603 	13.3% 	13.8% 	-0.5%
WW 	236 	218 	8.1% 	4.1% 	4.0% 	716 	639 	12.1% 	12.6% 	-0.5%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	379 	373 	1.5% 	1.5% 	- 	1,154 	1,032 	11.8% 	11.8% 	-
Intl 	147 	135 	9.1% 	12.1% 	-3.0% 	461 	534 	-13.7% 	-8.8% 	-4.9%
WW 	526 	508 	3.5% 	4.3% 	-0.8% 	1,615 	1,566 	3.1% 	4.8% 	-1.7%
OTHER INFECTIOUS DISEASES
US 	24 	33 	-26.6% 	-26.6% 	- 	79 	94 	-16.6% 	-16.6% 	-
Intl 	78 	80 	-2.3% 	-0.4% 	-1.9% 	252 	248 	1.8% 	6.3% 	-4.5%
WW 	102 	113 	-9.4% 	-8.1% 	-1.3% 	331 	342 	-3.2% 	0.0% 	-3.2%
% Change 	% Change

-- 2 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	759 	785 	-3.5% 	-3.5% 	- 	2,285 	2,172 	5.2% 	5.2% 	-
Intl 	846 	810 	4.5% 	4.1% 	0.4% 	2,565 	2,590 	-1.0% 	0.9% 	-1.9%
WW 	1,605 	1,595 	0.6% 	0.4% 	0.2% 	4,850 	4,762 	1.8% 	2.9% 	-1.1%
CONCERTA / Methylphenidate
US 	43 	84 	-49.2% 	-49.2% 	- 	150 	196 	-23.6% 	-23.6% 	-
Intl 	107 	109 	-2.0% 	-1.7% 	-0.3% 	319 	348 	-8.2% 	-6.4% 	-1.8%
WW 	149 	193 	-22.6% 	-22.5% 	-0.1% 	469 	544 	-13.8% 	-12.6% 	-1.2%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	585 	554 	5.6% 	5.6% 	- 	1,704 	1,543 	10.5% 	10.5% 	-
Intl 	341 	297 	14.9% 	12.6% 	2.3% 	983 	916 	7.3% 	8.6% 	-1.3%
WW 	926 	851 	8.8% 	8.0% 	0.8% 	2,688 	2,459 	9.3% 	9.8% 	-0.5%
RISPERDAL CONSTA
US 	70 	79 	-11.0% 	-11.0% 	- 	220 	237 	-6.9% 	-6.9% 	-
Intl 	81 	89 	-7.8% 	-8.9% 	1.1% 	254 	292 	-12.7% 	-11.0% 	-1.7%
WW 	152 	167 	-9.3% 	-9.9% 	0.6% 	475 	528 	-10.1% 	-9.2% 	-0.9%
OTHER NEUROSCIENCE
US 	60 	68 	-11.3% 	-11.3% 	- 	210 	196 	7.1% 	7.1% 	-
Intl 	317 	316 	0.3% 	1.7% 	-1.4% 	1,008 	1,035 	-2.6% 	-0.1% 	-2.5%
WW 	377 	384 	-1.8% 	-0.6% 	-1.2% 	1,218 	1,231 	-1.1% 	1.1% 	-2.2%
ONCOLOGY
US 	1,267 	1,171 	8.2% 	8.2% 	- 	3,623 	3,146 	15.2% 	15.2% 	-
Intl 	1,862 	1,590 	17.1% 	15.5% 	1.6% 	5,310 	4,830 	9.9% 	11.8% 	-1.9%
WW 	3,129 	2,761 	13.3% 	12.4% 	0.9% 	8,933 	7,976 	12.0% 	13.1% 	-1.1%
DARZALEX
US 	585 	402 	46.0% 	46.0% 	- 	1,540 	1,123 	37.2% 	37.2% 	-
Intl 	514 	363 	41.5% 	40.5% 	1.0% 	1,397 	1,045 	33.7% 	36.7% 	-3.0%
WW 	1,099 	765 	43.8% 	43.4% 	0.4% 	2,937 	2,168 	35.5% 	37.0% 	-1.5%
ERLEADA
US 	152 	74 	* 	* 	- 	407 	194 	* 	* 	-
Intl 	55 	12 	* 	* 	* 	112 	22 	* 	* 	*
WW 	206 	86 	* 	* 	* 	519 	216 	* 	* 	*
IMBRUVICA
US 	450 	447 	0.7% 	0.7% 	- 	1,329 	1,163 	14.2% 	14.2% 	-
Intl 	581 	475 	22.5% 	21.2% 	1.3% 	1,682 	1,373 	22.5% 	25.2% 	-2.7%
WW 	1,031 	921 	11.9% 	11.2% 	0.7% 	3,011 	2,536 	18.7% 	20.2% 	-1.5%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	105 	149 	-30.1% 	-30.8% 	0.7% 	311 	636 	-51.2% 	-50.7% 	-0.5%
WW 	105 	149 	-30.1% 	-30.8% 	0.7% 	311 	636 	-51.2% 	-50.7% 	-0.5%
ZYTIGA / abiraterone acetate
US 	58 	233 	-75.2% 	-75.2% 	- 	284 	616 	-53.9% 	-53.9% 	-
Intl 	532 	508 	4.8% 	2.2% 	2.6% 	1,564 	1,502 	4.1% 	4.8% 	-0.7%
WW 	590 	741 	-20.4% 	-22.1% 	1.7% 	1,848 	2,118 	-12.7% 	-12.3% 	-0.4%
OTHER ONCOLOGY
US 	21 	17 	35.3% 	35.3% 	- 	63 	51 	25.8% 	25.8% 	-
Intl 	76 	83 	-8.8% 	-10.1% 	1.3% 	244 	252 	-3.1% 	-1.1% 	-2.0%
WW 	98 	100 	-1.7% 	-2.8% 	1.1% 	308 	303 	1.7% 	3.3% 	-1.6%
PULMONARY HYPERTENSION
US 	510 	427 	19.4% 	19.4% 	- 	1,541 	1,296 	18.9% 	18.9% 	-
Intl 	239 	227 	5.2% 	3.7% 	1.5% 	742 	704 	5.3% 	6.5% 	-1.2%
WW 	749 	654 	14.5% 	13.9% 	0.6% 	2,283 	2,000 	14.1% 	14.6% 	-0.5%
OPSUMIT
US 	244 	206 	18.1% 	18.1% 	- 	729 	581 	25.3% 	25.3% 	-
Intl 	148 	140 	5.5% 	3.9% 	1.6% 	458 	419 	9.3% 	10.7% 	-1.4%
WW 	392 	347 	13.0% 	12.3% 	0.7% 	1,187 	1,001 	18.6% 	19.2% 	-0.6%
UPTRAVI
US 	226 	185 	22.4% 	22.4% 	- 	692 	536 	29.1% 	29.1% 	-
Intl 	34 	25 	32.3% 	28.9% 	3.4% 	100 	75 	33.1% 	34.6% 	-1.5%
WW 	260 	210 	23.6% 	23.2% 	0.4% 	792 	611 	29.6% 	29.8% 	-0.2%
OTHER PULMONARY HYPERTENSION
US 	40 	36 	11.5% 	11.5% 	- 	121 	179 	-32.3% 	-32.3% 	-
Intl 	57 	61 	-6.7% 	-7.4% 	0.7% 	183 	210 	-12.7% 	-11.9% 	-0.8%
WW 	97 	96 	0.1% 	-0.3% 	0.4% 	304 	388 	-21.7% 	-21.3% 	-0.4%
CARDIOVASCULAR / METABOLISM / OTHER
US 	931 	955 	-2.6% 	-2.6% 	- 	2,574 	2,804 	-8.2% 	-8.2% 	-
Intl 	351 	360 	-2.7% 	-2.4% 	-0.3% 	1,052 	1,131 	-7.1% 	-4.6% 	-2.5%
WW 	1,281 	1,316 	-2.6% 	-2.5% 	-0.1% 	3,625 	3,936 	-7.9% 	-7.2% 	-0.7%
XARELTO
US 	630 	613 	2.9% 	2.9% 	- 	1,716 	1,704 	0.7% 	0.7% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	630 	613 	2.9% 	2.9% 	- 	1,716 	1,704 	0.7% 	0.7% 	-
INVOKANA / INVOKAMET
US 	156 	125 	24.7% 	24.7% 	- 	405 	411 	-1.6% 	-1.6% 	-
Intl 	68 	55 	24.7% 	25.2% 	-0.5% 	173 	147 	18.0% 	20.7% 	-2.7%
WW 	224 	179 	24.7% 	24.9% 	-0.2% 	578 	558 	3.6% 	4.3% 	-0.7%
PROCRIT / EPREX
US 	69 	126 	-45.4% 	-45.4% 	- 	215 	387 	-44.5% 	-44.5% 	-
Intl 	63 	72 	-12.2% 	-13.0% 	0.8% 	208 	220 	-5.5% 	-4.3% 	-1.2%
WW 	132 	198 	-33.3% 	-33.6% 	0.3% 	423 	607 	-30.4% 	-29.9% 	-0.5%
OTHER
US 	75 	91 	-17.9% 	-17.9% 	- 	238 	302 	-21.4% 	-21.4% 	-
Intl 	219 	234 	-6.2% 	-5.5% 	-0.7% 	670 	765 	-12.3% 	-9.5% 	-2.8%
WW 	294 	325 	-9.5% 	-9.0% 	-0.5% 	908 	1,067 	-14.9% 	-12.9% 	-2.0%
TOTAL PHARMACEUTICAL
US 	6,438 	6,340 	1.5% 	1.5% 	- 	18,619 	17,705 	5.2% 	5.2% 	-
Intl 	4,980 	4,537 	9.7% 	8.8% 	0.9% 	14,685 	13,945 	5.3% 	7.4% 	-2.1%
WW 	11,418	$ 	10,877 	5.0% 	4.6% 	0.4% 	33,304	$ 	31,650 	5.2% 	6.1% 	-0.9%
See footnotes at end of schedule
% Change 	% Change

-- 3 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	399 	357 	11.8% 	11.8% 	- 	1,019 	1,066 	-4.4% 	-4.4% 	-
Intl 	437 	382 	14.0% 	12.9% 	1.1% 	1,134 	1,156 	-2.0% 	-1.0% 	-1.0%
WW 	836 	741 	12.9% 	12.4% 	0.5% 	2,153 	2,223 	-3.1% 	-2.7% 	-0.4%
ORTHOPAEDICS
US 	1,308 	1,301 	0.6% 	0.6% 	- 	3,427 	3,950 	-13.2% 	-13.2% 	-
Intl 	774 	837 	-7.5% 	-9.0% 	1.5% 	2,145 	2,616 	-18.0% 	-16.9% 	-1.1%
WW 	2,083 	2,138 	-2.6% 	-3.1% 	0.5% 	5,572 	6,566 	-15.1% 	-14.7% 	-0.4%
HIPS
US 	221 	204 	8.7% 	8.7% 	- 	564 	633 	-10.9% 	-10.9% 	-
Intl 	124 	133 	-7.2% 	-8.4% 	1.2% 	344 	428 	-19.8% 	-18.3% 	-1.5%
WW 	345 	336 	2.4% 	1.9% 	0.5% 	908 	1,061 	-14.5% 	-13.9% 	-0.6%
KNEES
US 	205 	209 	-1.9% 	-1.9% 	- 	527 	650 	-19.0% 	-19.0% 	-
Intl 	102 	136 	-24.8% 	-26.4% 	1.6% 	298 	435 	-31.5% 	-30.7% 	-0.8%
WW 	308 	344 	-10.9% 	-11.6% 	0.7% 	825 	1,085 	-24.0% 	-23.7% 	-0.3%
TRAUMA
US 	433 	415 	4.2% 	4.2% 	- 	1,194 	1,239 	-3.6% 	-3.6% 	-
Intl 	253 	262 	-3.4% 	-4.7% 	1.3% 	698 	795 	-12.2% 	-10.9% 	-1.3%
WW 	685 	677 	1.3% 	0.7% 	0.6% 	1,892 	2,034 	-7.0% 	-6.5% 	-0.5%
SPINE, SPORTS & OTHER
(7)
US 	449 	472 	-4.9% 	-4.9% 	- 	1,142 	1,427 	-20.0% 	-20.0% 	-
Intl 	295 	306 	-3.4% 	-5.0% 	1.6% 	805 	957 	-15.8% 	-14.9% 	-0.9%
WW 	745 	778 	-4.3% 	-5.0% 	0.7% 	1,947 	2,384 	-18.3% 	-18.0% 	-0.3%
SURGERY
US 	913 	940 	-3.0% 	-3.0% 	- 	2,247 	2,867 	-21.7% 	-21.7% 	-
Intl 	1,239 	1,371 	-9.6% 	-9.5% 	-0.1% 	3,556 	4,192 	-15.2% 	-13.1% 	-2.1%
WW 	2,152 	2,311 	-6.9% 	-6.9% 	0.0% 	5,803 	7,059 	-17.8% 	-16.6% 	-1.2%
ADVANCED
US 	421 	409 	3.0% 	3.0% 	- 	1,079 	1,209 	-10.7% 	-10.7% 	-
Intl 	579 	602 	-3.9% 	-4.1% 	0.2% 	1,644 	1,811 	-9.2% 	-7.3% 	-1.9%
WW 	1,000 	1,010 	-1.1% 	-1.2% 	0.1% 	2,723 	3,019 	-9.8% 	-8.7% 	-1.1%
GENERAL
US 	492 	531 	-7.6% 	-7.6% 	- 	1,168 	1,658 	-29.6% 	-29.6% 	-
Intl 	660 	769 	-14.1% 	-13.8% 	-0.3% 	1,912 	2,381 	-19.7% 	-17.5% 	-2.2%
WW 	1,152 	1,301 	-11.4% 	-11.3% 	-0.1% 	3,080 	4,040 	-23.8% 	-22.5% 	-1.3%
VISION
US 	473 	459 	3.1% 	3.1% 	- 	1,160 	1,366 	-15.1% 	-15.1% 	-
Intl 	608 	734 	-17.2% 	-17.4% 	0.2% 	1,683 	2,117 	-20.5% 	-19.6% 	-0.9%
WW 	1,081 	1,193 	-9.4% 	-9.5% 	0.1% 	2,843 	3,483 	-18.4% 	-17.8% 	-0.6%
CONTACT LENSES / OTHER
US 	375 	339 	10.9% 	10.9% 	- 	924 	993 	-6.9% 	-6.9% 	-
Intl 	455 	555 	-18.1% 	-18.2% 	0.1% 	1,274 	1,566 	-18.7% 	-17.8% 	-0.9%
WW 	830 	893 	-7.1% 	-7.2% 	0.1% 	2,198 	2,559 	-14.1% 	-13.6% 	-0.5%
SURGICAL
US 	98 	120 	-18.9% 	-18.9% 	- 	236 	373 	-36.8% 	-36.8% 	-
Intl 	153 	180 	-14.6% 	-14.8% 	0.2% 	409 	551 	-25.7% 	-24.8% 	-0.9%
WW 	251 	299 	-16.3% 	-16.4% 	0.1% 	645 	923 	-30.2% 	-29.6% 	-0.6%
TOTAL MEDICAL DEVICES
US 	3,092 	3,057 	1.2% 	1.2% 	- 	7,852 	9,249 	-15.1% 	-15.1% 	-
Intl 	3,058 	3,326 	-8.1% 	-8.5% 	0.4% 	8,518 	10,082 	-15.5% 	-14.1% 	-1.4%
WW 	6,150	$ 	6,383 	-3.6% 	-3.9% 	0.3% 	16,370	$ 	19,331 	-15.3% 	-14.6% 	-0.7%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 4 of 4 --